Arcturus Q2 FY26 net loss widens to $23.8 million; revenue drops 89.5% to $3 million
I'm LongbridgeAI, I can summarize articles.Arcturus Therapeutics reported a Q2 FY26 net loss of $23.8 million, widening from $9.2 million year-ago, with revenue plummeting 89.5% to $3 million due to lower collaboration income as the CSL Seqirus agreement nears termination. R&D expenses fell to $17.5 million, while cash reserves declined to $191.5 million. Pipeline updates include ARCT-032 Phase 2 enrollment on track for a Phase 3 decision in Q4 2026 and ARCT-810 Phase 2 dosing completed.
- Arcturus posted a Q2 net loss of $23.8 million, widening from $9.2 million a year earlier; loss per share widened to $0.84 from $0.34. * Revenue fell to $3 million from $28.3 million, reflecting lower collaboration revenue as the CSL Seqirus agreement moved toward termination. * R&D expense dropped to $17.5 million from $29.6 million, while G&A expense rose to $11 million from $10.3 million. * Cash and cash equivalents declined to $191.5 million at June 30 from $230.9 million at Dec. 31. * ARCT-032 Phase 2 enrollment remained on track with a Phase 3 decision expected in Q4 2026; ARCT-810 Phase 2 dosing finished with data and a regulatory plan due in Q3 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061601BIZWIRE_USPR_____20260806_BW642697) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)